Advancements and Collaborative Dynamics in the Treatment of Retinoblastoma: A Bibliometric Analysis of Trends and Themes.

IF 3.1 4区医学 Q2 OPHTHALMOLOGY

Seminars in Ophthalmology Pub Date : 2026-07-01 Epub Date: 2025-11-05 DOI:10.1080/08820538.2025.2584513

Jinying Gao, Peng Huang, Xue Leng, Yibing Zhang

{"title":"Advancements and Collaborative Dynamics in the Treatment of Retinoblastoma: A Bibliometric Analysis of Trends and Themes.","authors":"Jinying Gao, Peng Huang, Xue Leng, Yibing Zhang","doi":"10.1080/08820538.2025.2584513","DOIUrl":null,"url":null,"abstract":"Aim: This study aimed to provide a comprehensive bibliometric analysis of retinoblastoma treatment, assessing publication trends, influential research, and leading contributors.Methods: The research was conducted using the Web of Science Core Collection, focusing on retinoblastoma treatment from January 1, 1941, to June 13, 2024. Bibliometric analysis were conducted using Microsoft Excel, VOSviewer, CiteSpace, and the Bibliometrics R package.Results: The analysis identified 5,674 documents. The United States led in research output and citation impact, followed by China and Europe. The University of Toronto was the most prolific institution (488 articles). International collaborations accounted for 18.54% of publications. David H. Abramson was the most prolific author (139 articles), followed closely by C.L. Shields (100 articles). Keyword analysis revealed three major thematic clusters: (1) molecular mechanisms and oncogenesis, (2) cell cycle regulation and experimental models, and (3) clinical management and therapeutic strategies. Recent hotspots included intraarterial chemotherapy, melphalan, treatment resistance, risk stratification, and tumor biology. Retinoblastoma research centers on molecular mechanisms, cell cycle regulation, and clinical management.Conclusion: Advances in intraarterial chemotherapy, risk assessment, and molecular insights are improving survival and quality of life. Greater emphasis on real-world, multicenter, and international studies is needed to advance personalized care.","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"631-643"},"PeriodicalIF":3.1000,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08820538.2025.2584513","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/11/5 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: This study aimed to provide a comprehensive bibliometric analysis of retinoblastoma treatment, assessing publication trends, influential research, and leading contributors.

Methods: The research was conducted using the Web of Science Core Collection, focusing on retinoblastoma treatment from January 1, 1941, to June 13, 2024. Bibliometric analysis were conducted using Microsoft Excel, VOSviewer, CiteSpace, and the Bibliometrics R package.

Results: The analysis identified 5,674 documents. The United States led in research output and citation impact, followed by China and Europe. The University of Toronto was the most prolific institution (488 articles). International collaborations accounted for 18.54% of publications. David H. Abramson was the most prolific author (139 articles), followed closely by C.L. Shields (100 articles). Keyword analysis revealed three major thematic clusters: (1) molecular mechanisms and oncogenesis, (2) cell cycle regulation and experimental models, and (3) clinical management and therapeutic strategies. Recent hotspots included intraarterial chemotherapy, melphalan, treatment resistance, risk stratification, and tumor biology. Retinoblastoma research centers on molecular mechanisms, cell cycle regulation, and clinical management.

Conclusion: Advances in intraarterial chemotherapy, risk assessment, and molecular insights are improving survival and quality of life. Greater emphasis on real-world, multicenter, and international studies is needed to advance personalized care.

查看原文本刊更多论文

视网膜母细胞瘤治疗的进展和合作动态：趋势和主题的文献计量学分析。

目的：本研究旨在提供视网膜母细胞瘤治疗的综合文献计量分析，评估出版趋势、有影响力的研究和主要贡献者。方法：研究使用Web of Science核心馆藏进行，重点关注1941年1月1日至2024年6月13日期间视网膜母细胞瘤的治疗。使用Microsoft Excel、VOSviewer、CiteSpace和bibliometics R软件包进行文献计量学分析。结果：共鉴定出5674份文献。美国在研究产出和引文影响方面领先，其次是中国和欧洲。多伦多大学是发表论文最多的大学（488篇）。国际合作占18.54%。大卫·h·艾布拉姆森（David H. Abramson）是最多产的作者（139篇文章），其次是C.L.希尔兹（100篇文章）。关键词分析揭示了三个主要主题集群：(1)分子机制和肿瘤发生；(2)细胞周期调控和实验模型；(3)临床管理和治疗策略。最近的热点包括动脉化疗、美法兰、治疗耐药性、风险分层和肿瘤生物学。视网膜母细胞瘤的研究主要集中在分子机制、细胞周期调控和临床管理方面。结论：动脉内化疗、风险评估和分子洞察的进展正在改善生存率和生活质量。需要更多地强调现实世界、多中心和国际研究来推进个性化护理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Seminars in Ophthalmology OPHTHALMOLOGY-

CiteScore

3.20

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Seminars in Ophthalmology offers current, clinically oriented reviews on the diagnosis and treatment of ophthalmic disorders. Each issue focuses on a single topic, with a primary emphasis on appropriate surgical techniques.